BISPECIFIC ANTI-FLT3/CD3 ANTIBODIES AND METHODS OF USE

Provided herein are bispecific anti-FLT3/CD3 antibodies and antigen binding fragments thereof, such as the antibodies and fragments that specifically bind human FLT3 and human CD3. In some aspects, provided herein are optimized humanized, bispecific anti-FLT3/CD3 antibodies and antigen binding fragm...

Full description

Saved in:
Bibliographic Details
Main Authors LIANG, Raymond, ADER, Max Ephraim, SHRESTHA, Elina, SIROCHINSKY, Carina Rachel, SANDLER, Vladislav M, BEN JEHUDA, Ronen, KORYTKO, Andrew Ihor, CHILTON, Todd Christopher, SKORA, Andrew Dixon
Format Patent
LanguageEnglish
French
Published 23.02.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Provided herein are bispecific anti-FLT3/CD3 antibodies and antigen binding fragments thereof, such as the antibodies and fragments that specifically bind human FLT3 and human CD3. In some aspects, provided herein are optimized humanized, bispecific anti-FLT3/CD3 antibodies and antigen binding fragments thereof, optionally, having certain amino acid substitutions that confer advantageous properties (e.g., optimal antigen binding, manufacturability and/or half-life properties). Also provided herein are pharmaceutical compositions comprising such antibodies or fragments. Also provided herein are methods of use of such antibodies and fragments. L'invention concerne des anticorps bispécifiques anti-FLT3/CD3 et des fragments associés de liaison à l'antigène, tels que les anticorps et les fragments qui se lient spécifiquement à FLT3 humain et à CD3 humain. Selon certains aspects, la présente invention concerne des anticorps humanisés optimisés, des anticorps bispécifiques anti-FLT3/CD3 et des fragments associés de liaison à l'antigène, ayant éventuellement certaines substitutions d'acides aminés qui confèrent des propriétés avantageuses (par exemple, des propriétés optimales en termes de liaison à l'antigène, d'aptitude à la préparation et/ou de demi-vie. L'invention concerne également des compositions pharmaceutiques comprenant de tels anticorps ou fragments. L'invention concerne également des méthodes d'utilisation de ces anticorps et fragments.
Bibliography:Application Number: WO2022US74981